Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2001

View Archived Issues

Nycomed Amersham reports 2000 highlights, future name change

Reolysin induces reduction in tumor volume in mouse model

Ligand signs on Elan as third partner for oncology product commercialization

Regeneron reports follow-up results of phase II Axokine study

EpiGenesis enters agreement with Taisho; receives milestone payment from Chiesi

Dutch and U.S. alliance formed for familial hypercholesterolemia gene therapy

Immusol and Chugai establish functional genomics alliance

Genta begins new phase III with Genasense for treatment of CLL

Chelating drug to be codeveloped by Biomedical Frontiers and Chiesii

InterMune's Actimmune enters phase II for treatment of cystic fibrosis

Recently discovered protein for obesity expected to enter clinical trials in 2001

Relationship between CCK and functional dyspepsia examined using CCK-A antagonist

New triptan available for migraine therapy in the U.K.

Metformin during pregnancy safely reduces early spontaneous abortion in PCOS patients

Herzyme IND filed in Canada; Ribozyme anticipates initiation of phase I trials in Vancouver

D-Pharm and Lilly establish CNS collaboration

DepoCyt again available in the U.S. for lymphomatous meningitis

NCI supports development of Targesome's nanoparticle-based diagnostic imaging agents

CeNeS cleared to commence clinical trial of treatment for alcohol addiction

Non-CB1/CB2 cannabinoid receptor ligands and use in cardiovascular disorders

Nikken researchers describe new selective PDE4 inhibitors

Heterocyclic compounds from Sankyo act as Th1-selective immunosuppressants

U.S. and Japanese pharmaceutical companies pool resources to develop new antiviral agents

Merck KGaA presents new benzoylpyridazines as PDE4 and TNF inhibitors

Regulatory submissions filed for novel STI targeting abnormal protein in CML

Antineoplastic coumarone analogues identified at Sankyo

Antiinflammatory compounds in the Eisai pipeline

Anti-H. pylori dioxopiperazines discovered at Yamanouchi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...